• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Shablak, Alaaeldin
    Sikand, Kanwal A
    Shanks, Jonathan H
    Thistlethwaite, Fiona C
    Spencer-Shaw, Andrea
    Hawkins, Robert E
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
    Issue Date
    2011-01
    
    Metadata
    Show full item record
    Abstract
    Metastatic renal cancer remains hard to treat and the treatment is generally palliative. However, high-dose interleukin-2 (HD IL-2) produced 5% to 10% complete remissions and most of these were durable. With the advent of newer treatments with less toxicity, the role of HD IL-2 is uncertain. We present here a case series of 72 patients with metastatic renal cancer given first-line treatment with HD IL-2. From 2003 to 2006, the patients were offered treatment with HD IL-2 irrespective of their histologic features (retrospective cohort). From 2006 to 2008, the treatment was only offered to patients after stratification into risk groups based on histologic criteria (prospective cohort). In the early series, the response rate to HD IL-2 was 27% (8/30), but with prospective stratification of patients by histology the response rate was 52% (21/40) in the group with favorable histologic features. Combining outcome for all patients with the favorable histology (including those identified retrospectively) 49% (28/57) responded with 25% (14/57) achieving a complete remission and these seem durable. Patients with metastatic renal cancer should be carefully assessed for their suitability to undergo treatment with first-line systemic therapy with HD IL-2 as in carefully selected patients it has a high-rate response and durable remissions.
    Citation
    High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. 2011, 34 (1):107-12 J Immunother
    Journal
    Journal of Immunotherapy
    URI
    http://hdl.handle.net/10541/120269
    DOI
    10.1097/CJI.0b013e3181fb659f
    PubMed ID
    21150719
    Type
    Article
    Language
    en
    ISSN
    1537-4513
    ae974a485f413a2113503eed53cd6c53
    10.1097/CJI.0b013e3181fb659f
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
    • Authors: Negrier S, Maral J, Drevon M, Vinke J, Escudier B, Philip T
    • Issue date: 2000 Feb
    • Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    • Authors: Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC
    • Issue date: 1998 Mar-Apr
    • Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    • Authors: Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M
    • Issue date: 2008 Jul-Aug
    • An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    • Authors: Yang JC, Rosenberg SA
    • Issue date: 1997 Dec
    • Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    • Authors: McDermott DF, Atkins MB
    • Issue date: 2006 Oct
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.